Fosamax (Alendronate) and Osteonecrosis of the Jaw: Causation and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy heritage of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, discussions of bone health and pharmaceutical interventions have been standard, with a focus on therapeutic benefits and patient education. As the informational landscape evolves, a natural progression emerges toward examining specific exposure scenarios that arise from widespread medication use. This pivot is particularly relevant when considering the transition from general health awareness to occupational exposure concerns. In mass production environments, workers may encounter pharmaceutical compounds during manufacturing, packaging, or quality control processes. The shift from a general health context to a focused examination of Fosamax exposure and the associated risk of osteonecrosis of the jaw reflects a growing need to understand how routine industrial handling of such substances can lead to distinct health considerations. This transition acknowledges that while general health information provides a baseline, occupational settings introduce unique variables that warrant specialized attention. The bridge between these domains lies in recognizing that the same compounds discussed in patient-oriented literature can become occupational hazards when encountered repeatedly in production workflows.

Fosamax: Pharmacology and Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ).

Osteonecrosis of the Jaw: Clinical Presentation and Diagnosis

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation can occur spontaneously, but it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure or necrosis in the jaw that does not heal within eight weeks after identification. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Bisphosphonates like Fosamax inhibit osteoclast activity, which can suppress normal bone turnover and remodeling. In the jaw, which has high bone turnover rates, this suppression may impair healing after dental procedures or microtrauma, leading to necrosis. Additionally, the anti-angiogenic properties of bisphosphonates may reduce blood supply to the jawbone, further contributing to tissue death.

Risk Factors and Incidence of ONJ with Fosamax

Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In a cohort study among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). Most patients had relief of symptoms after stopping Fosamax, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Considerations

Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the condition, associated risk factors, and recommendations for management, including discontinuation for severe symptoms and consideration of drug holiday before invasive dental procedures. However, the labeling also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with jaw-related symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may complicate risk communication. For affected patients, causation considerations involve assessing the temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer, radiation therapy, or other medications. The presence of known risk factors, such as dental procedures or corticosteroid use, may contribute to the development of ONJ. The duration of Fosamax exposure is a key factor, as risk increases with longer use. Discontinuation of Fosamax may lead to symptom relief, and rechallenge with the same or another bisphosphonate can cause recurrence, supporting a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The absolute risk remains low, but the association is well-documented in medical literature.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure or necrosis that does not heal within eight weeks after identification (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the duration of Fosamax use affect ONJ risk?

The risk of ONJ increases with longer duration of bisphosphonate use. In a cohort study, ONJ risk was threefold higher after 2-3 years and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702).

Can stopping Fosamax reverse ONJ symptoms?

Most patients experience relief of symptoms after stopping Fosamax, but a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.